Thirteen patients have been enrolled to date, and among the first nine evaluable patients, the combination therapy has demonstrated an overall pathological response of 88%, a major pathological complete response (MPR), meaning a significant reduction in cancer cells, was achieved in 55% of patients, and an even stronger pathological complete response (pCR), meaning no remaining viable tumor cells, was achieved in 44% of patients, states the company. Additionally, the treatment has a favorable safety profile, and no patient has relapsed to date.

The study is being conducted at Oslo University Hospital – The Norwegian Radium Hospital.

These interim findings emphasize ruxotemitide’s unique intratumoral, immunogenic cell-death mechanism, which alters the tumor microenvironment and triggers a robust systemic anti-tumor immune response prior to surgery. Lytix Biopharma remains highly encouraged by these findings, which demonstrate the potential of ruxotemitide in this patient population.

“The interim results from this neoadjuvant study in resectable melanoma, coupled with our extensive body of clinical data from studies evaluating ruxotemitide both as monotherapy and in combination with pembrolizumab, reinforce our confidence in its potential,” said Øystein Rekdal, PhD, Founder and CEO of Lytix Biopharma.